Terms: = Leukemia AND DNMT3A, Q9Y6K1, 1788, ENSG00000119772, DNMT3A2, M_HsaIIIA AND Treatment
251 results:
1. Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.
Risueño A; See WL; Bluemmert I; de Botton S; DiNardo CD; Fathi AT; Schuh AC; Montesinos P; Vyas P; Prebet T; Gandhi A; Hasan M
Leuk Res; 2024 May; 140():107497. PubMed ID: 38564986
[TBL] [Abstract] [Full Text] [Related]
2. Sweet syndrome induced by FLT3 inhibitors: case report and literature review.
Yang L; Zhang R; Ma H
Hematology; 2024 Dec; 29(1):2337230. PubMed ID: 38563968
[TBL] [Abstract] [Full Text] [Related]
3. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.
Patnaik MM; Tefferi A
Am J Hematol; 2024 Jun; 99(6):1142-1165. PubMed ID: 38450850
[TBL] [Abstract] [Full Text] [Related]
4. The crossroads of cancer therapies and clonal hematopoiesis.
Singh A; Balasubramanian S
Semin Hematol; 2024 Feb; 61(1):16-21. PubMed ID: 38403501
[TBL] [Abstract] [Full Text] [Related]
5. Mechanisms of action and resistance in histone methylation-targeted therapy.
Yamagishi M; Kuze Y; Kobayashi S; Nakashima M; Morishima S; Kawamata T; Makiyama J; Suzuki K; Seki M; Abe K; Imamura K; Watanabe E; Tsuchiya K; Yasumatsu I; Takayama G; Hizukuri Y; Ito K; Taira Y; Nannya Y; Tojo A; Watanabe T; Tsutsumi S; Suzuki Y; Uchimaru K
Nature; 2024 Mar; 627(8002):221-228. PubMed ID: 38383791
[TBL] [Abstract] [Full Text] [Related]
6. CALCRL knockdown suppresses cancer stemness and chemoresistance in acute myeloid leukemia with FLT3-ITD and DNM3TA-R882 double mutations.
Tang S; Zhu H; Sheng L; Mu Q; Wang Y; Xu K; Zhou M; Xu Z; Wu A; Ouyang G
Drug Dev Res; 2024 Feb; 85(1):e22137. PubMed ID: 38349260
[TBL] [Abstract] [Full Text] [Related]
7. Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy.
Weng G; Huang J; An N; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; He X; Jin H; Liu Q; Du X
Cancer Med; 2024 Jan; 13(2):e6885. PubMed ID: 38334500
[TBL] [Abstract] [Full Text] [Related]
8. Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
Johnson IM; Karrar O; Rana M; Iftikhar M; Chen S; McCullough K; Saliba AN; Al-Kali A; Alkhateeb H; Begna K; Litzow M; Hogan WJ; Shah M; Patnaik MM; Pardanani A; Hermann J; Tefferi A; Gangat N
Br J Haematol; 2024 Apr; 204(4):1232-1237. PubMed ID: 38311378
[TBL] [Abstract] [Full Text] [Related]
9. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A; Vannucchi AM; Barbui T
Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
[TBL] [Abstract] [Full Text] [Related]
10. Chidamide, Decitabine, Cytarabine, Aclarubicin, and Granulocyte Colony-stimulating Factor Therapy for Patients with Relapsed/Refractory Acute Myeloid leukemia: A Retrospective Study from a Single-Center.
Kong FC; Qi L; Zhou YL; Yu M; Huang WF; Li F
Curr Med Sci; 2023 Dec; 43(6):1151-1161. PubMed ID: 38057538
[TBL] [Abstract] [Full Text] [Related]
11. The ferroptosis landscape in acute myeloid leukemia.
Ma Z; Ye W; Huang X; Li X; Li F; Lin X; Hu C; Wang J; Jin J; Zhu B; Huang J
Aging (Albany NY); 2023 Nov; 15(22):13486-13503. PubMed ID: 38032290
[TBL] [Abstract] [Full Text] [Related]
12. Oncolytic Activity of Canine Distemper Virus in Human Ductal Breast Carcinoma Cells.
Jhala D; Nathani N; Joshi M; Patel A; Joshi CG
Oncol Res Treat; 2024; 47(1-2):10-17. PubMed ID: 38008084
[TBL] [Abstract] [Full Text] [Related]
13. DNMTs-mediated SOCS3 methylation promotes the occurrence and development of AML.
Zhang X; Zhang K; Zhang J; Chang W; Zhao Y; Suo X
Eur J Haematol; 2024 Mar; 112(3):439-449. PubMed ID: 37950514
[TBL] [Abstract] [Full Text] [Related]
14. Genomic Mutation Profiles of Patients with Acute Myeloid leukemia in Korea: a Single-Center Experience.
Han E; Ryu S; Kim D; Koh EH; Byun JH; Lee DH
Clin Lab; 2023 Nov; 69(11):. PubMed ID: 37948498
[TBL] [Abstract] [Full Text] [Related]
15. Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation.
Williams LS; Williams KM; Gillis N; Bolton K; Damm F; Deuitch NT; Farhadfar N; Gergis U; Keel SB; Michelis FV; Panch SR; Porter CC; Sucheston-Campbell L; Tamari R; Stefanski HE; Godley LA; Lai C
Transplant Cell Ther; 2024 Mar; 30(3):255-267. PubMed ID: 37913908
[TBL] [Abstract] [Full Text] [Related]
16. Identification of Cell Type-Specific Effects of
Bae SG; Kim HJ; Kim MY; Kim DDH; Shin SI; Ahn JS; Park J
Mol Cells; 2023 Oct; 46(10):611-626. PubMed ID: 37853686
[TBL] [Abstract] [Full Text] [Related]
17. Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML.
Li H; Wang Y; Feng S; Chang K; Yu X; Yang F; Huang H; Wang Y; Li X; Guan F
Cell Commun Signal; 2023 Sep; 21(1):255. PubMed ID: 37736724
[TBL] [Abstract] [Full Text] [Related]
18. Molecular and clinical significance of FLT3, NPM1, dnmt3a and TP53 mutations in acute myeloid leukemia patients.
Ali AM; Salih GF
Mol Biol Rep; 2023 Oct; 50(10):8035-8048. PubMed ID: 37540457
[TBL] [Abstract] [Full Text] [Related]
19. Clinical features and prognostic significance of dnmt3a, FLT3, and NPM1 mutations in de novo acute myeloid leukemia patients.
Chen M; Zeng Z; Li X; Qin W; Cai X; Chen S; Lu X
Int J Lab Hematol; 2023 Dec; 45(6):899-907. PubMed ID: 37519024
[TBL] [Abstract] [Full Text] [Related]
20. SFXN3 is Associated with Poor Clinical Outcomes and Sensitivity to the Hypomethylating Therapy in Non-M3 Acute Myeloid leukemia Patients.
Dong Y; Jin F; Wang J; Li Q; Huang Z; Xia L; Yang M
Curr Gene Ther; 2023; 23(5):410-418. PubMed ID: 37491851
[TBL] [Abstract] [Full Text] [Related]
[Next]
